Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M Yamamoto, A Kurita, T Asahara… - Oncology …, 2008 - spandidos-publications.com
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
[引用][C] Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M Yamamoto - Oncol Rep, 2008 - cir.nii.ac.jp
[PDF][PDF] Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M YAMAMOTO, A KURITA, T ASAHARA… - ONCOLOGY …, 2008 - scholar.archive.org
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M Yamamoto, A Kurita, T Asahara… - Oncology …, 2008 - pubmed.ncbi.nlm.nih.gov
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
M Yamamoto, A Kurita, T Asahara, A Takakura… - Oncology …, 2008 - europepmc.org
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M Yamamoto, A Kurita, T Asahara… - Oncology …, 2008 - spandidos-publications.com
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M YAMAMOTO, A KURITA, T ASAHARA… - ONCOLOGY …, 2008 - ingentaconnect.com
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …
[引用][C] Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
M YAMAMOTO, A KURITA, M YOKOBA… - Oncology …, 2008 - pascal-francis.inist.fr
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …